Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7- hydroxylation

Thrombosis Research

Volumn 88, Issue 4, 1997, Pages 389-398

  Zhang, Zhi Yi ^a   Kerr, Janet ^b   Wexler, Roseanne S ^b   Li, Hui Yin ^b   Robinson, Andrea J ^b   Harlow, Patricia P ^b   Kaminsky, Laurence S ^a,c  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b DUPONT COMPANY   (United States)

^c WADSWORTH CENTER   (United States)

Author keywords

CYP2C9; Warfarin; Warfarin drug interactions

Indexed keywords

7 FLUOROWARFARIN; 7 HYDROXYWARFARIN; COUMARIN DERIVATIVE; CYTOCHROME P450 ISOENZYME; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; HUMAN; LIVER MICROSOME METABOLISM; METABOLIC REGULATION; PRIORITY JOURNAL; STEREOCHEMISTRY;

ARYL HYDROCARBON HYDROXYLASES; BINDING, COMPETITIVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES, LIVER; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; WARFARIN;

EID: 0031573045     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00270-3     Document Type: Article

References (38)

1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 6:1996;1-42.
2. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991;256:1189-94.
3. Ged C, Umbenhauer DR, Bellew TM, Bork RW, Srivastava PK, Shinriki N, Lloyd RS, Guengerich FP. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylase. Biochemistry 1988;27:6929-40.
4. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991;30:3247-55.
5. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 1989;28:4993-9.
6. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, Mcmanus ME. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin. Pharmacol 1991;31:125-30.
7. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
8. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990; 252:442-7.
9. Srivastava PK, Yun C-H, Beaune PH, Ged C, Guengerich FP Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol. 40:1991;69-79.
10. Veronese ME, MacKenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991;175:1112-8.
11. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54-9.
12. Kaminsky LS, De Morais SMF, Faletto MB, Dunbar DA, Goldstein, JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol Pharmacol 1993;43:234-9.
13. Brian WR, Ged C, Bellew TM, Srivastava PK, Bork RW, Umbenhauer DR, Lloyd RS, Guengerich FP. Human liver mephenytoin 4′-hydroxylase cytochrome P-450 proteins and genes. Drug Metab Rev 1989;20:449-65.
14. Sandhu P, Baba T, Guengerich FP. Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys 1993;306:443-50.
15. Lopez Garcia MP, Dansette PM, Valadon P, Amar C, Beaune PH, Guengerich FP, Mansuy, D. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies - Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur J Biochem 1993;213:223-32.
16. Weaver RJ, Dickins M, Burke MD Hydroxylation of the antimalarial drug 58C80 by CYP2C9 in human liver microsomes: comparison with mephenytoin and tolbutamide hydroxylations. Biochem Pharmacol. 49:1995;997-1004.
17. Zhao J, Leemann T, Dayer P. In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450. Life Sci 1992;51:575-81.
18. Newlands AJ, Smith DA, Jones BC, Hawksworth GM Metabolism of non-steroidal anti inflammatory drugs by cytochrome P4502C. Br J Clin Pharmacol. 34:1992;152P.
19. Leemann T, Transon C, Bonnabry P, Dayer P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal anti inflammatory drugs. Drugs Exp Clin Res 1993;19:189-95.
20. Leemann T, Bonnabry P, Dayer P. Proceedings of the 14th European Workshop on Drug Metabolism. Paris; 1994. p. 140.
21. Leemann T, Transon C, Dayer P Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci. 52:1993;29-34.
22. Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Disp 1995;23:207-15.
23. Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exper Ther 1995;272:1076-81.
24. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KR. Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 1995;49:1269-75.
25. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
26. Kunze KL, Eddy AC, Gibaldi M, Trager WF. Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 1991;3:24-9.
27. West BD, Preis S, Schroeder CH, Link KP. Studies on the 4-hydroxy-coumarins. XVII. The resolution and absolute configuration of warfarin. J Am Chem Soc 1961;83:2676-9.
28. Kaminsky LS, Fasco MJ, Guengerich FP. Production and application of antibodies to rat liver cytochrome P-450. Methods Enzymol 1981;74:262-72.
29. Pohl L, Haddock R, Garland WA, Trager, W. Synthesis and thin layer chromatographic, ultraviolet, and mass spectral properties of the anticoagulant phenoprocoumon and its monohydroxylated derivatives. J Med Chem 1975;18:513-9.
30. Buckle DR, Cantello B, Smith H, Spicer B. Antiallergic activity of 4-hydroxy-3-nitrocoumarins. J Med Chem 1975;18:391-4.
31. Fasco MJ, Piper LJ, Kaminsky LS. Biochemical applications of a quantitative high pressure liquid chromatographic assay of warfarin and its metabolites. J Chromatog 1977;131:365-73.
32. Hermodsen MA, Barker WM, Link KP. Studies on the 4- hydroxycoumarins. Synthesis of the metabolites and some other derivatives of warfarin. J Med Chem 1971;14:167-9.
33. Li H-Y, Boswell GA. A facile synthesis of fluorinated 4-hydroxycoumarins. Tetrahedron Lett 1996;37:1551-4.
34. Robinson A, Li H-Y, Feaster J. A "chiralswitch": The first practical asymmetric synthesis of R- and S-warfarin. Tetrahedron Lett 1996; 37:8321-4.
35. Cnubben NHP, Vervoort J, Boersma MG, Rietjens IMCM. The effect of varying halogen substituent patterns on the cytochrome P450 catalysed dehalogenation of 4-halogenated anilines to 4-aminophenol metabolites. Biochem Pharmacol 1995;49:1235-48.
36. Heimark LD, Trager WF. The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system. J Med Chem 1984;27:1092-5.
37. Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: An approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 1995;34:10365-75.
38. Darbyshire JF, Iyer KR, Grogan J, Korzekwa KR, Trager WF. Selectively deuterated warfarin: Substrate probe for the mechanism of aromatic hydroxylation catalysed by cytochrome P-450. Proceedings of the 4th International ISSX Meeting. Seattle, WA; 1995. p. 267.